Robinson, Jennifer G.

2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines

Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Circulation

Lipoproteins and Cardiovascular HealthHealth Promotion and Cardiovascular Prevention

Cited by 7,081

2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk

Goff, D. C., Lloyd-Jones, D. M., Bennett, G., Coady, S., D’Agostino, R. B., Gibbons, R., Greenland, P., Lackland, D. T., Levy, D., O’Donnell, C. J., et al. (2014) · Journal of the American College of Cardiology

Health Promotion and Cardiovascular PreventionCoronary Interventions and Diagnostics

Cited by 4,945

2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults

Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Journal of the American College of Cardiology

Lipoproteins and Cardiovascular HealthHealth Promotion and Cardiovascular Prevention

Cited by 3,845

2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines

Goff, D. C., Lloyd-Jones, D. M., Bennett, G., Coady, S., D’Agostino, R. B., Gibbons, R., Greenland, P., Lackland, D. T., Levy, D., O’Donnell, C. J., et al. (2014) · Circulation

Health Promotion and Cardiovascular PreventionLipoproteins and Cardiovascular Health

Cited by 3,697

Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events

Robinson, J. G., Farnier, M., Krempf, M., Bergeron, J., Luc, G., Averna, M., Stroes, E. S., Langslet, G., Raal, F. J., El Shahawy, M., et al. (2015) · New England Journal of Medicine

Lipoproteins and Cardiovascular HealthLipid metabolism and disorders

Cited by 2,296

Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events

Sabatine, M. S., Giugliano, R. P., Wiviott, S. D., Raal, F. J., Blom, D. J., Robinson, J., Ballantyne, C. M., Somaratne, R., Legg, J., Wasserman, S. M., et al. (2015) · New England Journal of Medicine

Lipoproteins and Cardiovascular HealthAtherosclerosis and Cardiovascular Diseases

Cited by 1,509

Dietary fats and cardiovascular disease: a presidential advisory from the American Heart Association

Sacks, F. M., Lichtenstein, A. H., Wu, J. H. Y., Appel, L. J., Creager, M. A., Kris-Etherton, P. M., Miller, M., Rimm, E. B., Rudel, L. L., Robinson, J. G., et al. (2017) · Circulation

Fatty Acid Research and HealthNutritional Studies and Diet

Cited by 1,386

Variation in PCSK9 and HMGCR and Risk of Cardiovascular Disease and Diabetes

Ference, B. A., Robinson, J. G., Brook, R. D., Catapano, A. L., Chapman, M. J., Neff, D. R., Voros, S., Giugliano, R. P., Davey Smith, G., Fazio, S., et al. (2016) · New England Journal of Medicine

Lipoproteins and Cardiovascular HealthGenetic Associations and Epidemiology

Cited by 743

HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials

Swerdlow, D. I., Preiss, D., Kuchenbaecker, K. B., Holmes, M. V., Engmann, J. E. L., Shah, T., Sofat, R., Stender, S., Johnson, P. C. D., Scott, R. A., et al. (2015) · The Lancet

Lipoproteins and Cardiovascular HealthGenetic Associations and Epidemiology

Cited by 680

Familial Hypercholesterolemia: Screening, diagnosis and management of pediatric and adult patients

Goldberg, A. C., Hopkins, P. N., Toth, P. P., Ballantyne, C. M., Rader, D. J., Robinson, J. G., Daniels, S. R., Gidding, S. S., de Ferranti, S. D., Ito, M. K., et al. (2011) · Journal of clinical lipidology

Lipoproteins and Cardiovascular HealthLipid metabolism and disorders

Cited by 622

Association Between Baseline LDL-C Level and Total and Cardiovascular Mortality After LDL-C Lowering: A Systematic Review and Meta-analysis

Navarese, E. P., Robinson, J. G., Kowalewski, M., Kolodziejczak, M., Andreotti, F., Bliden, K., Tantry, U., Kubica, J., Raggi, P., & Gurbel, P. A. (2018) · JAMA

Lipoproteins and Cardiovascular HealthCancer, Lipids, and Metabolism

Cited by 549

Familial Hypercholesterolemia: Screening, diagnosis and management of pediatric and adult patients

Goldberg, A. C., Hopkins, P. N., Toth, P. P., Ballantyne, C. M., Rader, D. J., Robinson, J. G., Daniels, S. R., Gidding, S. S., de Ferranti, S. D., Ito, M. K., et al. (2011) · Journal of Clinical Lipidology

Lipoproteins and Cardiovascular HealthLipid metabolism and disorders

Cited by 545

Omega-3 Fatty Acids for the Management of Hypertriglyceridemia: A Science Advisory From the American Heart Association

Skulas-Ray, A. C., Wilson, P. W. F., Harris, W. S., Brinton, E. A., Kris-Etherton, P. M., Richter, C. K., Jacobson, T. A., Engler, M. B., Miller, M., Robinson, J. G., et al. (2019) · Circulation

Fatty Acid Research and HealthLipid metabolism and disorders

Cited by 512

Effect of Evolocumab or Ezetimibe Added to Moderate- or High-Intensity Statin Therapy on LDL-C Lowering in Patients With Hypercholesterolemia: The LAPLACE-2 Randomized Clinical Trial

Robinson, J. G., Nedergaard, B. S., Rogers, W. J., Fialkow, J., Neutel, J. M., Ramstad, D., Somaratne, R., Legg, J. C., Nelson, P., Scott, R., et al. (2014) · JAMA

Lipoproteins and Cardiovascular HealthCholesterol and Lipid Metabolism

Cited by 496

Cognitive function in a randomized trial of evolocumab

Giugliano, R. P., Mach, F., Zavitz, K., Kurtz, C., Im, K., Kanevsky, E., Schneider, J., Wang, H., Keech, A., Pedersen, T. R., et al. (2017) · New England Journal of Medicine

Lipoproteins and Cardiovascular HealthDementia and Cognitive Impairment Research

Cited by 492

Optimism, Cynical Hostility, and Incident Coronary Heart Disease and Mortality in the Women’s Health Initiative

Tindle, H. A., Chang, Y.-F., Kuller, L. H., Manson, J. E., Robinson, J. G., Rosal, M. C., Siegle, G. J., & Matthews, K. A. (2009) · Circulation

Optimism, Hope, and Well-beingCardiac Health and Mental Health

Cited by 483

Meta-Analysis of the Relationship Between Non–High-Density Lipoprotein Cholesterol Reduction and Coronary Heart Disease Risk

Robinson, J. G., Wang, S., Smith, B. J., & Jacobson, T. A. (2009) · Journal of the American College of Cardiology

Lipoproteins and Cardiovascular HealthCholesterol and Lipid Metabolism

Cited by 368

Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: The ODYSSEY COMBO I study

Kereiakes, D. J., Robinson, J. G., Cannon, C. P., Lorenzato, C., Pordy, R., Chaudhari, U., & Colhoun, H. M. (2015) · American Heart Journal

Lipoproteins and Cardiovascular HealthCholesterol and Lipid Metabolism

Cited by 349

Sex Differences in the Use of Statins in Community Practice: Patient and Provider Assessment of Lipid Management Registry

Nanna, M. G., Wang, T. Y., Xiang, Q., Goldberg, A. C., Robinson, J. G., Roger, V. L., Virani, S. S., Wilson, P. W. F., Louie, M. J., Koren, A., et al. (2019) · Circulation: Cardiovascular Quality and Outcomes

Lipoproteins and Cardiovascular HealthSex and Gender in Healthcare

Cited by 313

Patient‐Reported Reasons for Declining or Discontinuing Statin Therapy: Insights From the PALM Registry

Bradley, C. K., Wang, T. Y., Li, S., Robinson, J. G., Roger, V. L., Goldberg, A. C., Virani, S. S., Louie, M. J., Lee, L. V., Peterson, E. D., et al. (2019) · Journal of the American Heart Association

Lipoproteins and Cardiovascular HealthMedication Adherence and Compliance

Cited by 286

Blood n-3 fatty acid levels and total and cause-specific mortality from 17 prospective studies

Harris, W. S., Tintle, N. L., Imamura, F., Qian, F., Korat, A. V. A., Marklund, M., Djoussé, L., Bassett, J. K., Carmichael, P.-H., Chen, Y.-Y., et al. (2021) · Nature Communications

Fatty Acid Research and HealthNutritional Studies and Diet

Cited by 244

Safety of Very Low Low-Density Lipoprotein Cholesterol Levels With Alirocumab

Robinson, J. G., Rosenson, R. S., Farnier, M., Chaudhari, U., Sasiela, W. J., Merlet, L., Miller, K., & Kastelein, J. J. P. (2017) · Journal of the American College of Cardiology

Lipoproteins and Cardiovascular HealthAntiplatelet Therapy and Cardiovascular Diseases

Cited by 197

No effect of PCSK9 inhibitor alirocumab on the incidence of diabetes in a pooled analysis from 10 ODYSSEY phase 3 studies

Colhoun, H. M., Ginsberg, H. N., Robinson, J. G., Leiter, L. A., Müller-Wieland, D., Henry, R. R., Cariou, B., Baccara-Dinet, M. T., Pordy, R., Merlet, L., et al. (2016) · European Heart Journal

Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 172

Higher RBC EPA + DHA corresponds with larger total brain and hippocampal volumes: WHIMS-MRI Study

Pottala, J. V., Yaffe, K., Robinson, J. G., Espeland, M. A., Wallace, R., & Harris, W. S. (2014) · Neurology

Fatty Acid Research and HealthDementia and Cognitive Impairment Research

Cited by 169